Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novacyt ( (FR:ALNOV) ) just unveiled an announcement.
Novacyt S.A. has provided an update on its liquidity agreement with Invest Securities SA, detailing the purchase and sale of ordinary shares during July 2025. The company reported that 14,521 shares were purchased and 8,516 shares were sold under the agreement. The total number of ordinary shares in the company is 70,626,248, which shareholders can use for interest calculations. This update reflects Novacyt’s ongoing efforts to manage its share liquidity and maintain transparency with its stakeholders.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a comprehensive range of integrated technologies and services, primarily focusing on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation, providing solutions across sectors such as human health, animal health, and environmental. Novacyt operates in three business segments: Clinical, Instrumentation, and Research Use Only, with a presence in over 65 countries and headquarters in Le Vésinet, France.
See more data about ALNOV stock on TipRanks’ Stock Analysis page.